Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Napro Biotherapeutics Charts. Click Here for more Napro Biotherapeutics Charts.](/p.php?pid=staticchart&s=N%5ENPRO&p=8&t=15)
Stephen K. Carter, M.D. Joins NaPro Board of Directors
BOULDER, Colo., March 10 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc.
announced today the appointment of Stephen K. Carter, M.D. to its Board of
Directors effective March 9, 2004.
Dr.Carter has over forty years of experience in oncology and pharmaceutical
drug development as a practicing clinician, medical researcher, Clinical
Professor of Medicine (University of California, San Francisco) and a senior
member of the National CancerInstitute (NCI). In addition, Dr. Carter served
as a pharmaceutical executive for thirteen years at Bristol-Myers Squibb where
he held the position of Senior Vice President, Worldwide Clinical Research and
Development.
At the National Cancer Institute Dr. Carter held the position of Deputy
Director, Division of Cancer Treatment, where, for over a decade, he helped
shape the cancer therapy evaluation branch of the NCI. Later, at Bristol- Myers
Squibb, Dr. Carter was responsible for the development of a number of cancer
chemotherapeutics including both Carboplatin and Taxol.
"All of us at NaPro welcome the integrity, broad experience, and judgment that
Dr. Carter brings to both our commercial and medical deliberations as we advance
our preclinical portfolio of anticancer agents into human clinical trials over
the next year," commented Leonard Shaykin, Chairman and Chief Executive Officer
of NaPro. "We are honored by Dr. Carter's participation in the Company and look
forward to his contributionon the Board."
In a related matter, Marc J. Ostro, Ph.D., a Managing Director of T.L. Ventures,
has decided to resign from the Board of NaPro BioTherapeutics effective March
11, 2004.
About NaPro BioTherapeutics
NaPro BioTherapeutics, Inc., is a life science company focused on the
development of therapies for the treatment of cancer and hereditary disease.
Forward Looking Statements
The statements in this news release that are not historical facts are
forward-looking statements that represent management's beliefs and assumptions
as of the date of this news release, based on currently available information.
Although the Company believes that the expectations reflected in such forward-
looking statements are reasonable, it cannot assure that these expectations will
prove to be correct. Such statements involve risks and uncertainties including:
risks associated with development of anti-cancer agents, including competition
from companies in similar businesses, limitations on the ability to market
products because of the intellectual property rights of third parties, the
ability to obtain, maintain and enforce patents; the costs of continuing
development of any or all of the Company's development programs; the timing of
when those programs will enter the clinic; the successful commercialization of
the Company's platform technologies; the fact that the Company's business will
require substantial additional investment that the Company has not secured; and
the risk that the Company's cash not be sufficient to fund the Company's
strategic plans for the initial development new proprietary therapeutic
candidates; and all of those factors identified under the captions "Risk
Factors," "Special Note Regarding Forward Looking Statements" or "Cautionary
Note Regarding Forward Looking Statements" in the Company's documents filed from
time to time with the SEC, including the Company's registration statement on
Form S-3, as amended, dated August 8, 2003, its Annual Report on Forms 10-K and
10-K/A for the year ending December 31, 2002 filed with the SEC on March 27,
April 30, August 8 and October 24, 2003, and its Quarterly Report on Form 10-Q
for the quarter ended October 1, 2003 filed with the Securities and Exchange
Commission on November 14, 2003. Should one or more of these risks materialize
(or the consequences of such a development worsen), or should the underlying
assumptions prove incorrect, actual results could differ materially from those
forecasted or expected. The Company disclaims any intention or obligation to
update publicly or revise such statements whether as a result of new
information, future events or otherwise.
DATASOURCE: NaPro BioTherapeutics, Inc.
CONTACT: L. Robert Cohen, Vice President, Investor Relations of NaPro
BioTherapeutics, Inc., +1-212-218-8715; or Investors, Lilian Stern of Stern
Investor Relations, +1-212-362-1200; or Media, Peter Steinerman,
+1-516-374-3031, both for NaPro BioTherapeutics, Inc.
Web site: http://www.naprobio.com/